Autonomix shares surge 56.8% after-hours on positive pancreatic cancer trial subgroup results showing sustained quality-of-life improvements.

Autonomix Medical (NASDAQ: AMIX) surged 56.81% in after-hours trading following the release of positive subgroup analysis results from its first-in-human proof-of-concept study for pancreatic cancer pain ablation therapy. The data demonstrated sustained improvements in quality of life, with stage 4 patients showing 32.48-point symptom reductions and 25.56-point functional gains at 3 months, exceeding EORTC thresholds for clinical significance. CEO Brad Hauser highlighted the therapy’s potential to address advanced disease, while the findings will guide a U.S. multicenter trial set to begin in 2026. The results, including nearly 60% pain reduction and opioid-free outcomes, reinforced investor optimism about the company’s market expansion into visceral cancer pain management.